Full Year 2025 Oxford Biomedica PLC Earnings Call Transcript
Key Points
- Oxford BioMedica PLC (OXBDF) achieved a 33% increase in revenues at constant currency for 2025, reaching £170.9 million, reflecting strong demand for their CDMO services.
- The company reported its first full year of operating EBITDA profitability, with an operating profit of £8.1 million, compared to a loss of £15.3 million in 2024.
- Oxford BioMedica PLC (OXBDF) strengthened its financial position by securing long-term capital through a £60 million fundraising and a new loan facility, providing financial flexibility for future investments.
- The acquisition of an FDA-approved commercial-scale viral vector manufacturing facility in Durham, North Carolina, expanded their US commercial capabilities and supported late-stage programs.
- The company has a strong commercial momentum, with a 36% increase in backlog to £204 million and a 20% increase in contracted client orders to £224 million, providing strong revenue visibility into 2026 and beyond.
- The first half of 2026 is expected to be loss-making at the EBITDA level due to planned routine maintenance shutdowns and non-recurring costs linked to technology transfers and integration of the Durham facility.
- There is a potential risk of overcapacity at the Bedford site, as the expansion plans were halted in favor of the Durham acquisition.
- The company faces competition in the CDMO market, with some competitors struggling, which could impact market dynamics.
- The integration of the Durham facility and technology transfers are ongoing, which may pose operational challenges and require significant resources.
- The company's growth is heavily reliant on the successful execution of its strategic priorities and maintaining strong client demand, which could be impacted by market fluctuations or regulatory changes.
Hello and welcome to OXB 2025 preliminary results. We are joined today by Dr. Frank Matthias, Chief Executive Officer, Dr. Lucinda Crabtree, Chief Financial Officer, and Dr. Sebastian Ribault, Chief Business Officer. If you would like to ask a question during today's call, please press one on your telephone keypad, or you can submit a written question via the toolbar below.
I would now like to hand the call over to Doctor Frank Matthias. Please go ahead.
Thank you so much for the introduction. Good morning to those in the US and good afternoon to everyone else, and thank you for joining our OXB preliminary results briefing for the full year of 2025.
Presenting alongside I just mentioned, with me today is our Chief Financial Officer, Doctor Lucy Crabtree, as well as our Chief Business Officer, Doctor Sebastian.
Next slide, please.
Before we begin, Sorry, one back. Yeah, sorry.
Before we begin, I will quickly run through today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
